Clinical Trial Update: Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing mild Alzheimer's disease progression in participants on solanezumab vs placebo; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Solanezumab (solanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-03-14